Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Why Cenovus Energy stock is down today: Venezuela shock hits Canadian oil sands

Why Cenovus Energy stock is down today: Venezuela shock hits Canadian oil sands

Toronto, Jan 5, 2026, 14:19 (EST) — Regular session Cenovus Energy Inc shares fell more than 5% on Monday afternoon, tracking a selloff in Canadian oil sands producers as investors weighed whether Venezuela’s heavy crude could re-enter U.S. markets and pressure Canadian pricing. The U.S.-listed stock was down 5.3% at $16.60, after touching a session low of $15.81. The slide matters because Venezuela and Western Canada both sell heavy crude, a thicker grade that needs complex refineries to process. Any policy shift that speeds Venezuelan flows back toward U.S. Gulf Coast refineries risks narrowing the “scarcity premium” that has supported
5 January 2026
····
Fabrinet stock slides nearly 7% today as contract manufacturers sell off; earnings in focus

Fabrinet stock slides nearly 7% today as contract manufacturers sell off; earnings in focus

New York, Jan 5, 2026, 14:29 EST — Regular session Fabrinet (NYSE:FN) shares fell about 6.7% on Monday, bucking a rise in the broader market. The stock was down $32.06 at $447.36 by 2:29 p.m. EST, after swinging between $490.18 and $440.00. The S&P 500 and Nasdaq were up about 0.7% and 0.8%, respectively. The move matters because Fabrinet sits deep in the hardware supply chain, providing optical packaging — the assembly and testing of optical components — and other precision manufacturing services for complex products. That leaves the stock sensitive to shifts in demand from equipment makers serving telecom
5 January 2026
·······
Sunrun stock slides as RUN lags solar peers with jobs report, Goldman conference in focus

Sunrun stock slides as RUN lags solar peers with jobs report, Goldman conference in focus

New York, Jan 5, 2026, 14:26 EST — Regular session Sunrun Inc shares fell 5.6% on Monday, a sharp underperformer in U.S. solar, as investors weighed fresh U.S. economic data and looked ahead to a key jobs report later this week. The stock was down $1.08 at $18.36 in afternoon trade. The move matters because Sunrun’s rooftop solar business leans heavily on financing, and shifts in interest-rate expectations can quickly change customer economics and investor appetite for the sector. Traders were also scanning for any read-through on demand and pricing as the first full week of 2026 gets underway. Reuters
5 January 2026
····
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

New York, January 5, 2026, 14:21 EST — Regular session Shares of Viking Therapeutics (VKTX) slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%. The move highlights how sensitive obesity-drug developers remain to pricing signals from the market leaders. Viking has no approved products, so changes in expected pricing can hit the stock as hard as trial data. Direct-to-consumer discounts are also changing how investors think about margins
5 January 2026
······
Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

New York, January 5, 2026, 1:09 PM ET — Regular session Wave Life Sciences Ltd shares fell $1.34, or 8.4%, to $14.61 in afternoon trade on Monday, extending a sharp pullback in the clinical-stage biotech even as the company flagged an investor-conference appearance next week. The move matters because the J.P. Morgan Healthcare Conference often sets the tone for biotech investing early in the year, and Wave’s stock has become closely tethered to expectations for updates on its obesity program and financing needs. Biotech lagged more broadly, with the SPDR S&P Biotech ETF down about 2.1% and the iShares Nasdaq
5 January 2026
····
Gulfport Energy stock (GPOR) slides nearly 9% on Wolfe downgrade as gas prices fall

Gulfport Energy stock (GPOR) slides nearly 9% on Wolfe downgrade as gas prices fall

New York, Jan 5, 2026, 13:05 EST — Regular session Gulfport Energy Corporation shares fell 8.7% on Monday after Wolfe Research analyst Carlos Escalante cut the U.S. gas producer to Peer Perform from Outperform. The stock traded at $188.26 after swinging between $209.00 and $187.93. GuruFocus The call matters now because investors have been repricing gas-linked cash flows as the fuel’s latest pullback deepens. U.S. natural gas fell about 3.5% to $3.49 per million British thermal units, according to TradingEconomics data. Trading Economics Escalante wrote that Wolfe lowered its long-term U.S. gas price forecast by 25 cents to $4.00 per
5 January 2026
·····
SiTime stock slumps 9% after topping Wall Street targets, bucking chip rally

SiTime stock slumps 9% after topping Wall Street targets, bucking chip rally

New York, Jan 5, 2026, 13:54 EST — Regular session SiTime Corp shares slid about 9% on Monday afternoon, reversing an earlier rise and wiping out a chunk of the timing-chip maker’s start-of-year gains. The Nasdaq-listed stock was down $33.46 at $336.50, after trading as high as $382 and as low as $333.33. The move matters because SiTime has become a high-beta way to play the semiconductor cycle, and investors are reassessing richly valued niche chip names as 2026 gets underway. A sharp intraday turn like Monday’s often signals fast money leaving crowded positions, even when the broader sector is
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

NEW YORK, Jan 5, 2026, 13:54 EST — Regular session Structure Therapeutics shares fell 7.7% to $62.86 in afternoon trade on Monday, paring an earlier rally and marking another volatile session for the obesity-drug developer. The stock has ranged from $72.02 to $62.50 so far in the regular session. The move came as Novo Nordisk began U.S. sales of a once-daily pill version of Wegovy, bringing a branded oral option into pharmacies at $149 a month for starter doses for self-paying patients, Reuters reported. Novo’s website shows higher-dose pricing at $299 a month, with the 4 mg dose set to
5 January 2026
······
Astera Labs stock drops 8% after insider sale plan disclosed — what traders watch next

Astera Labs stock drops 8% after insider sale plan disclosed — what traders watch next

New York, Jan 5, 2026, 13:45 EST — Regular session Astera Labs shares fell 8.4% to $164.50 on Monday, after swinging from a session high near $185 to a low around $162.5. More than 5 million shares had traded by early afternoon. The move matters because Astera has become a high-volatility proxy for investor appetite for AI infrastructure spending, where sentiment can turn quickly on positioning and supply. A sharp reversal early in the year can amplify stop-loss selling and make intraday liquidity more fragile. Insider-selling signals draw extra attention in fast-rising semiconductor names, even when the amounts are small
5 January 2026
·····
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

New York, Jan 5, 2026, 13:31 EST — Regular session Arrowhead Pharmaceuticals shares were down about 6.9% on Monday after the company said Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock fell $4.68 to $63.11 after swinging between $60.75 and $70.87. MarketScreener The clearance gives Arrowhead another regulated market for its first commercial product, as investors shift attention from the science to execution. It also keeps the spotlight on how quickly the company can convert approvals into reimbursed prescriptions. The selloff underscored how hard it can be for single-stock catalysts to cut through sector tape.
5 January 2026
·····
AAOI stock slides nearly 11% after $41 pop; what Applied Optoelectronics investors watch next

AAOI stock slides nearly 11% after $41 pop; what Applied Optoelectronics investors watch next

New York, Jan 5, 2026, 13:30 EST — Regular session Applied Optoelectronics, Inc. (AAOI) shares fell nearly 11% on Monday, erasing an early jump that briefly lifted the stock above $41. The retreat came even as broader U.S. equities and chip-related names traded higher, underlining how quickly positioning can flip in the optical components maker. Applied Optoelectronics sells optical transceivers — plug-in hardware that converts electrical signals into light to move data through fiber. Why it matters now: the stock has become a high-beta proxy for capital spending on AI-linked data centers, where demand is shifting toward faster links. Investors
5 January 2026
····
Lumentum stock drops 8% in sharp reversal as optics peers slide; Feb. 5 earnings loom

Lumentum stock drops 8% in sharp reversal as optics peers slide; Feb. 5 earnings loom

New York, Jan 5, 2026, 13:11 (ET) — Regular session Shares of Lumentum Holdings Inc (LITE.O) fell 8.1% to $354.87 on Monday, after trading between $345 and $394.48 in a volatile session. About 4.2 million shares had changed hands by early afternoon. The slide puts one of the market’s most closely watched optics names back under pressure after a late-2025 run that pushed the stock toward record territory. The move matters now because expectations for AI-linked data-center optics have risen fast, and that leaves less tolerance for a softer outlook when companies next report. Optical components are laser-based parts that
5 January 2026
····
1 … 412 413 414 415 416 … 883

Stock Market Today

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

7 February 2026
Rio Tinto’s U.S. shares closed up 2.5% at $93.37 Friday after the company ruled out a merger with Glencore, triggering a six-month “no-bid” lockout under UK takeover rules. Both companies cited disagreements over valuation. Attention now turns to Rio’s Feb. 19 results and iron ore prices, which fell below $100 a tonne amid weak Chinese demand.
iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST share price drops 3% as markets shut; earnings next week in focus

7 February 2026
iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.
Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

7 February 2026
Sembcorp shares closed at S$6.05 on Friday, down 0.33%, as Singapore’s STI dropped 0.8%. Shareholders approved the A$6.5 billion Alinta Energy takeover on Jan 30, but the deal still faces regulatory and closing conditions. Sembcorp will release FY2025 results on Feb 25 before market open. Trading volume reached about 4.3 million shares.
Go toTop